Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumors (A58456) - R14 - Effective October 1, 2025

Date Posted: October 23, 2025

This Billing and Coding Article has been revised under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).

Effective Date: October 1, 2025

Summary of Changes:

Under Group 2 Paragraph, updated the statement from "Signatera tests for monitoring the response to immune-checkpoint inhibitor (ICI) therapy" to "This group includes tests for monitoring the response to immune-checkpoint inhibitor (ICI) therapy."

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.

Last Updated $dateUtil.getDate( $modifieddate , "MMM dd , yyyy" , $locale , $tzone )